Los Angeles Capital Management LLC Acquires 23,160 Shares of Accuray Incorporated (NASDAQ:ARAY)

Los Angeles Capital Management LLC boosted its holdings in shares of Accuray Incorporated (NASDAQ:ARAY) by 10.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 255,378 shares of the medical equipment provider’s stock after buying an additional 23,160 shares during the quarter. Los Angeles Capital Management LLC owned approximately 0.25% of Accuray worth $506,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. SG Americas Securities LLC increased its holdings in shares of Accuray by 37.4% during the 4th quarter. SG Americas Securities LLC now owns 45,079 shares of the medical equipment provider’s stock worth $89,000 after acquiring an additional 12,259 shares during the last quarter. Assenagon Asset Management S.A. boosted its position in Accuray by 28.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 212,330 shares of the medical equipment provider’s stock worth $420,000 after purchasing an additional 47,331 shares during the period. Virtu Financial LLC acquired a new position in shares of Accuray in the third quarter valued at $244,000. Barclays PLC raised its position in shares of Accuray by 97.9% in the third quarter. Barclays PLC now owns 210,819 shares of the medical equipment provider’s stock valued at $380,000 after purchasing an additional 104,310 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of Accuray by 2.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,179,396 shares of the medical equipment provider’s stock worth $3,924,000 after buying an additional 45,548 shares during the last quarter. Institutional investors own 64.08% of the company’s stock.

Accuray Price Performance

Accuray stock opened at $1.92 on Tuesday. The company has a market capitalization of $197.44 million, a price-to-earnings ratio of -38.40 and a beta of 1.51. The company has a current ratio of 1.62, a quick ratio of 0.88 and a debt-to-equity ratio of 3.51. Accuray Incorporated has a 12 month low of $1.40 and a 12 month high of $2.95. The stock’s 50 day moving average is $2.17 and its 200-day moving average is $2.03.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.02 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.03. Accuray had a negative return on equity of 9.75% and a negative net margin of 0.96%. Equities research analysts expect that Accuray Incorporated will post 0.01 EPS for the current year.

Analysts Set New Price Targets

Separately, StockNews.com lowered shares of Accuray from a “buy” rating to a “hold” rating in a research note on Tuesday, February 18th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.